Korro Bio, Inc.
KRRONasdaq
$12.25
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↓ -6.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$142.1M
Enterprise Value
$28.1M
P/E
—
P/S
37.0
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
-49.7%
Dividend Yield
—
Revenue (TTM)
$3.8M
Net Income (TTM)
-$113.5M
Free Cash Flow (TTM)
-$70.6M
Gross Margin
—
Operating Margin
-3052.3%
Net Margin
-2954.1%
ROE
-94.9%
ROIC
-1636.0%
Debt / Equity
—
Net Cash
$114.0M
Return 1Y
-11.4%
Company profile
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
- CEO
- Ram Aiyar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Massachusetts
- Website
- www.korrobio.com
Management & directors
- Cerio JeffreyGeneral Counsel
- Chappell ToddChief Operating Officer
- Dolan OliverSenior Vice President, Finance
- Vincent Loic AChief Scientific Officer
- Aiyar RamPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
KRRO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$1.69↓ -32.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $37.0M | $14.1M | $0.00 | $0.00 | $2.3M | $6.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.6M | -$84.0M | -$59.0M | -$84.5M | -$91.9M | -$121.9M |
| Net income | -$26.5M | -$84.7M | -$58.0M | -$81.2M | -$83.6M | -$117.3M |
| Diluted EPS | — | — | -$227.42 | -$53.08 | -$9.37 | -$12.48 |
| Operating cash flow | -$45.2M | -$76.1M | -$53.6M | -$67.3M | -$60.1M | -$78.6M |
| Free cash flow | -$51.9M | -$79.0M | -$58.8M | -$75.1M | -$78.0M | -$79.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -74.5% | -597.3% | — | — | -4047.1% | -1906.4% |
| Net margin | -71.7% | -602.0% | — | — | -3680.4% | -1834.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.3M | $2.5M | $1.5M | $1.1M | $1.3M | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.1M | -$23.3M | -$23.0M | -$25.0M | -$27.2M | -$19.2M | -$50.4M | -$20.4M |
| Net income | -$21.8M | -$21.0M | -$21.2M | -$23.4M | -$25.8M | -$18.1M | -$50.0M | -$19.6M |
| Diluted EPS | -$2.43 | -$2.26 | -$2.24 | -$2.49 | -$2.74 | -$1.92 | -$5.33 | -$1.69 |
| Operating cash flow | -$14.6M | -$16.1M | -$7.5M | -$24.5M | -$19.2M | -$17.2M | -$17.7M | -$16.1M |
| Free cash flow | -$20.6M | -$21.0M | -$8.9M | -$24.6M | -$19.4M | -$17.4M | -$17.8M | -$16.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -1014.5% | -981.2% | -1863.2% | -1764.9% | -3900.6% | — |
| Net margin | — | — | -933.5% | -917.1% | -1765.1% | -1657.0% | -3873.2% | — |
Company news
Jul 10, 2026
Jul 8, 2026
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Dolan Oliver· Senior Vice President, Finance | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-07-15 | Cerio Jeffrey· General Counsel | Award | 6,500 | $0.00 | $0.00 | filing |
| 2026-07-15 | Chappell Todd· Chief Operating Officer | Award | 7,500 | $0.00 | $0.00 | filing |
| 2026-07-15 | Vincent Loic A· Chief Scientific Officer | Award | 7,500 | $0.00 | $0.00 | filing |
| 2026-07-06 | FORMELA JEAN FRANCOIS | Sale | 8,506 | $13.96 | $118,743.76 | filing |
| 2026-07-06 | FORMELA JEAN FRANCOIS | Sale | 817 | $13.96 | $11,405.32 | filing |
| 2026-07-02 | FORMELA JEAN FRANCOIS | Sale | 85,955 | $14.03 | $1.2M | filing |
| 2026-07-02 | FORMELA JEAN FRANCOIS | Sale | 14,745 | $14.03 | $206,872.35 | filing |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Sale | 40,679 | $14.60 | $593,913.40 | filing |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Sale | 6,979 | $14.60 | $101,893.40 | filing |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Sale | 666 | $14.98 | $9,976.68 | filing |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Sale | 114 | $14.98 | $1,707.72 | filing |
| 2026-06-23 | FORMELA JEAN FRANCOIS | Sale | 101,579 | $14.25 | $1.4M | filing |
| 2026-06-23 | FORMELA JEAN FRANCOIS | Sale | 17,426 | $14.25 | $248,320.50 | filing |
| 2026-06-22 | FORMELA JEAN FRANCOIS | Sale | 3,382 | $13.95 | $47,178.90 | filing |
| 2026-06-22 | FORMELA JEAN FRANCOIS | Sale | 580 | $13.95 | $8,091.00 | filing |
| 2026-06-16 | Cerio Jeffrey· General Counsel | Sale | 6,609 | $10.83 | $71,575.47 | filing |
| 2026-06-16 | Vincent Loic A· Chief Scientific Officer | Sale | 3,418 | $10.83 | $37,016.94 | filing |
| 2026-06-16 | Dolan Oliver· Senior Vice President, Finance | Sale | 3,383 | $10.83 | $36,637.89 | filing |
| 2026-06-16 | Chappell Todd· Chief Operating Officer | Sale | 3,168 | $10.83 | $34,309.44 | filing |
| 2026-05-29 | Aiyar Ram· President and CEO | Sale | 15,152 | $12.98 | $196,672.96 | filing |
| 2026-05-28 | FORMELA JEAN FRANCOIS | Sale | 2,441 | $13.95 | $34,051.95 | filing |
| 2026-05-28 | FORMELA JEAN FRANCOIS | Sale | 419 | $13.95 | $5,845.05 | filing |
| 2026-05-26 | Aiyar Ram· President and CEO | Award | 50,000 | $12.33 | $616,500.00 | filing |
| 2026-03-31 | Lynx1 Capital Management LP | Buy | 520 | $10.60 | $5,512.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.